In a research report issued Tuesday, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Prosensa Holding (NASDAQ:RNA) with a price target of $25, following …
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target, as …
In a research report issued Tuesday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $45 price target, as longer …
In a research report released today, analyst Christopher Marai of Oppenheimer maintained an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target, which represents a potential …
In a research report issued today, Oppenheimer analyst Christopher Marai maintained an Outperform rating on MacroGenics (NASDAQ:MGNX) with a $48 price target, as the …
In a research report issued today, Oppenheimer analyst Christopher Marai assigned an Outperform rating on PTC Therapeutics (NASDAQ:PTCT) with a $60 price target. Marai …
